Meiji Yasuda Asset Management’s Royalty Pharma RPRX Stock Holding History

Meiji Yasuda Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$454K	Buy	8,098 +320	+4%	+$16.7K	0.02%	383
2026 Q1	$373K	Sell	7,778 -280	-3%	-$12.3K	0.02%	391
2025 Q4	$311K	Buy	8,058 +523	+7%	+$19.9K	0.02%	428
2025 Q3	$266K	Buy	7,535 +80	+1%	+$2.9K	0.01%	450
2025 Q2	$269K	Sell	7,455 -4,497	-38%	-$149K	0.01%	449
2025 Q1	$372K	Hold	11,952	–	–	0.02%	495
2024 Q4	$305K	Hold	11,952	–	–	0.01%	543
2024 Q3	$338K	Hold	11,952	–	–	0.01%	524
2024 Q2	$315K	Hold	11,952	–	–	0.01%	523
2024 Q1	$363K	Buy	11,952 +1,090	+10%	+$32.1K	0.02%	496
2023 Q4	$305K	Buy	+10,862	New	+$298K	0.01%	467

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Meiji Yasuda Asset Management's RPRX Position: Q2 2026 in Review

Meiji Yasuda Asset Management increased its Royalty Pharma (RPRX) stake by 4.1% in Q2 2026, buying an estimated $16.7K and bringing the position to 8,098 shares worth $454K. The position accounts for 0.02% of the portfolio, ranked #383.

Meiji Yasuda Asset Management first reported a position in RPRX in Q4 2023 and has held it in 11 quarters since. 643 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

Meiji Yasuda Asset Management held 8,098 shares of Royalty Pharma worth $454K as of Q2 2026.
Meiji Yasuda Asset Management bought 320 Royalty Pharma shares in Q2 2026, an estimated $16.7K.
Royalty Pharma made up 0.02% of Meiji Yasuda Asset Management's portfolio in Q2 2026, its #383 holding.
Meiji Yasuda Asset Management first reported a position in Royalty Pharma in Q4 2023 and has held it in 11 quarters since.
643 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Meiji Yasuda Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.